Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-05-09
2006-05-09
Gupta, Anish (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C514S006900, C604S403000, C604S408000
Reexamination Certificate
active
07041800
ABSTRACT:
The invention relates to a method for preserving the stability of a hemoglobin blood substitute comprising maintaining the hemoglobin blood substitute in an atmosphere substantially free of oxygen. The method for preserving a deoxygenated hemoglobin blood substitute comprises maintaining the deoxygenated hemoglobin blood substitute in an oxygen barrier film overwrap package. In one embodiment, the package comprises a transparent laminate material comprising an oxygen barrier layer and a polyolefin layer, wherein the laminant has a thickness of between about 0.001 and about 0.01 inches (or about 0.0254 to about 0.254 millimeters) and an oxygen permeability of less than about 0.01 cubic centimeters per 100 square inches (or about 0.01 cc per 645 square centimeters) over 24 hours at 1 atmosphere and at about 23° C. The oxygen barrier layer comprises ethylene vinyl alcohol. Aso provided herein is a preserved deoxygenated hemoglobin blood substitute comprises a deoxygenated hemoglobin blood substitute and an oxygen barrier film overwrap package. The package comprises a transparent laminant material comprising an oxygen barrier layer and a polyolefin layer. Said oxygen barrier layer has an oxygen permeability of less than about 0.01 cubic centimeters per 100 square inches (or about 0.01 cc per 645 square centimeters) over 24 hours at 1 atmosphere and at about 27° C. room temperature, wherein the deoxygenated hemoglobin blood substitute is sealed within the overwrap package. In one embodiment, the oxygen barrier layer comprises ethylene vinyl alcohol.
REFERENCES:
patent: 4001200 (1977-01-01), Bonsen et al.
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4053590 (1977-10-01), Bonsen et al.
patent: 4061736 (1977-12-01), Morris et al.
patent: 4140162 (1979-02-01), Gajewski et al.
patent: 4460365 (1984-07-01), Ganshirt et al.
patent: 4561110 (1985-12-01), Herbert
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4699816 (1987-10-01), Galli
patent: 4778697 (1988-10-01), Genske et al.
patent: 4826811 (1989-05-01), Sehgal
patent: 4826955 (1989-05-01), Akkapeddi et al.
patent: 4857636 (1989-08-01), Hsia
patent: 4861867 (1989-08-01), Estep
patent: 5045529 (1991-09-01), Chiang
patent: 5051353 (1991-09-01), Stratton et al.
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5100401 (1992-03-01), Patel
patent: 5167657 (1992-12-01), Patel
patent: 5178884 (1993-01-01), Goodrich et al.
patent: 5189146 (1993-02-01), Hsia
patent: 5194590 (1993-03-01), Sehgal et al.
patent: 5234903 (1993-08-01), Nho et al.
patent: 5264555 (1993-11-01), Shorr et al.
patent: 5281360 (1994-01-01), Hong et al.
patent: 5296465 (1994-03-01), Rausch et al.
patent: 5296466 (1994-03-01), Kilbourn et al.
patent: 5322161 (1994-06-01), Shichman et al.
patent: 5334706 (1994-08-01), Przybelski
patent: 5352773 (1994-10-01), Kandler et al.
patent: 5356709 (1994-10-01), Woo et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5683768 (1997-11-01), Shang et al.
patent: 5929031 (1999-07-01), Kerwin et al.
patent: 6127043 (2000-10-01), Lange
patent: 39 15252 (1990-11-01), None
patent: 2 107 191 (1983-04-01), None
patent: 06249848 (1994-09-01), None
patent: WO 89/12456 (1989-12-01), None
Antonini, E. et al., “Sickling and Hemoglobin S Gelation,” InMethods in Enzymology vol. 76 Hemoglobins, eds. (NY:Academic Press), pp. 765, 769-770 (1981).
Biro, G.P. et al., “Early Deleterious Hemorheologic Changes Following Acute Experimental Coronary Occlusion and Salutary Antihyperviscosity Effect of Hemodilution with Stroma-Free Hemoglobin,”American Heart Journal, 103(5) :870-878 (1992).
Biro, G.P. and Beresford-Kroeger, D., “The Effect of Hemodilution with Stroma-Free Hemoglobin and Dextran on Collateral Perfusion of Ischemic Myocardium in the Dog,”American Heart Journal, 99(1) :64-75 (1980).
Chu, D., et al., Abstract 80.13., “The Effect of Hemodilution with a Purified Monomer or Purified Bovine Hemoglobin on Infarct Size in Focal Ischemia in Rabbits,”Society for Neuroscience Abstracts, 20:180 (1994), presented at the 24thAnnual Meeting Society of Neuroscience, Miami Beach, FL (Nov. 13-18, 1994).
Cole, D. J. et al., “Focal Cerebral Ischemia in Rats: Effect of Hypervolemic Hemodilution with Disapirin Cross-Linked HemoglobinversusAlbumin on Brain Injury and Edema,”Anesthesiology, 78(2):335-342 (1993).
Cole, D. J. et al., “Focal Cerebral Ischemia in Rats: Effect of Hemodilution with α-α Cross-Linked Hemoglobin on CBF,”J. Cereb. Blood Flow Metab., 12 (6) :971-976 (1992).
Cole, D. J. et al., “Effects of Viscosity and Oxygen Content on Cerebral Blood Flow in Ischemic and Normal Rat Brain,”Journal of Neurological Sciences, 124:15-20 (1994).
DeVenuto, F., “Stability of Hemoglobin Solution During Extended Storage,”J. Lab. Clin. Med., 92(6) :946-952 (Dec. 1975).
Dodrill, R. et al., “Barrier Coated Polyester Films for Healthcare Packaging,” Conference Paper Presented at the Polyester in Healthcare Packaging, pp. 1-17 [online] (1996) [retrieved on Apr. 28, 1999] Retrieved from the Internet <URL:http://www.rollprint.com
ews/barrier.htm>.
Feola, M. et al., “Clinical Trail of a Hemoglobin Based Blood Substitute in Patients with Sickle Cell Anemia,”SURGERY, Gynecology&Obstetrics, 174:379-386 (1992).
Feola, M. et al., “Improved Oxygenation of Ischemic Mycardium by Hemodilution with Stroma-Free Hemoglobin Solution,”CHEST, 75(3) :369-375 (1979).
“Film Preserves Blood Substitute,”Pharmaceutical&Medical Packaging News, [online] (Jul. 1998) [retrieved on Oct. 28, 2002]. Retrieved from the Internet <URL:http://www.devicelink.com/pmpn/archive/98/07/012.html>.
Hamilton, P. et al., “Preparation of Hemoglobin Solutions for Intravenous Infusion,”Hemoglobin Solution, pp. 455-463.
Hauser, C. J. and Shoemaker, W.C., “Hemoglobin Solution in the Treatment of Hemorrhagic Shock,”Critical Care Medicine, 10(4) :283-287 (1982).
Homer, L.D. et al., “Oxygen Gradients Between Red Blood Cells in the Microcirculation,”Hypoxia Between Red Cells, Academic Press, Inc. 308-323 (1981).
Krieter, H. et al., “Effects of stroma-free polymerized bovine hemoglobin solution on oxygen transport, Global and regional blood flow in a canine model of stepwise hemodilution,”Anesth. Anal., 78(2) S226 (1994).
Leone, B.J., and Spahn, D.R., “Anemia, Hemodilution, and Oxygen Delivery,”Anesth. Analg. 75:651-653 (1992).
Paradis, N.A. et al., “Selective aortic perfusion and oxygenation: An effective adjunct to external chest compression-based cardiopulmonary resusitation,”J. American College of Cardiology, 23(2), 497-504 (1994).
Sarelius, I.H., Cell and Oxygen Flow in Arterioles Controlling Capillary PerfusionAm. J. Physiol. 265 (Heart Circ. Physiol. 34): H1682-H1687 (1993).
Standl, T. et al., “Hemodynamics and Oxygen Transport During Complete Isovolemic Hemodilution With a New Ultrapurified Polymerized Bovine Hemoglobin Solution in a Dog Model,” Paper presented at the Annual Meeting of the American Society of Anesthesiologists, Washington (1993) and at the Central European Congress of Anaesthesiology, Dresden (1993).
Teicher, B.A. et al., “Oxygenation of tumors by a hemoglobin solution,”J. Cancer Research and Clinical Onco120:85-90 (1993).
Tsai, A.G. and Intaglietta, M., “Local Tissue Oxygenation During Constant Red Blood Cell Flux: A Discrete Source Analysis of Velocity and Hematocrit Changes,”Microvascular Research, 37:308-322 (1989).
Waschke, K. et al., “Local Cerebral Blood Flow and Glucose Utilization After Blood Exchange with A Hemoglobin-Based O2Carrier in Conscious Rats,”Amer. J. Physiol., 265, 1234-H1248 (Jun. 1993).
Wei, E.P. et al., “Effect of Local Change in O2Saturation of Hemoglobin on Cerebral Vasodilution from Hypoxia and Hypotension ,”Am. J. Physiol., 265 (Heart Circ. Physiol. 34) :H1439-H1443 (1993).
Gawryl Maria S.
Houtchens Robert A.
Light William R.
Biopure Corporation
Gupta Anish
Hamilton Brook Smith & Reynolds P.C.
LandOfFree
Preserving a hemoglobin blood substitute with a transparent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preserving a hemoglobin blood substitute with a transparent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preserving a hemoglobin blood substitute with a transparent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3538658